<DOC>
	<DOCNO>NCT00801294</DOCNO>
	<brief_summary>The primary objective trial explore overall objective best response rate rate non-progression 16 week sequential , alternate weekly administration BIBF 1120 BIBW 2992 patient metastatic CRC base RECIST criterion .</brief_summary>
	<brief_title>A Phase II Trial Weekly Alternating Sequential Administration BIBF 1120 BIBW 2992 Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>1 . Age 18 year . 2 . Signed informed consent . 3 . Histologically proven colorectal adenocarcinoma 4 . History presence metastatic colorectal cancer ( stage IV ) 5 . Measurable ( &gt; 1 cm ) evaluable tumour deposit ( accord RECIST criterion ) 6 . Documented progression unacceptable toxicity last therapy 7 . Progression oxaliplatinbased chemotherapy unacceptable residual neurotoxicity oxaliplatin 8 . Progression irinotecanbased chemotherapy unacceptable toxicity irinotecan 9 . If patient previously expose Cetuximab EGFR inhibitor , must show progression unacceptable toxicity 10 . If patient previously expose Bevacizumab VEGF inhibitor , must show progression unacceptable toxicity 11 . Life expectancy least 12 week . 12. WHO ( ECOG ) performance status &lt; = 2 , &lt; = 1 age &gt; 75 year . 13 . Adequate hepatic function 14 . Adequate renal function 1 . Prior treatment small molecule EGFR , HER2 VEGFR tyrosine kinase inhibitor 2 . Treatment standard chemotherapy cetuximab within last 14 day 3 . Treatment bevacizumab within last 28 day 4 . History malignancy last 5 year , could affect compliance protocol interpretation result . Patients adequately treat basal squamous cell skin cancer generally eligible . 5 . Serious illness concomitant nononcological disease neurologic , psychiatric , infectious disease active ulcer ( gastrointestinal tract , skin ) laboratory abnormality 6 . Significant cardiovascular disease 7 . History haemorrhagic thrombotic event past 12 month . Known inherited predisposition bleeds thrombosis . 8 . Patient history clinical radiological evidence CNS disease brain metastasis . 9 . Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>